bremelanotide + RAAS inhibition therapy

Combination therapy of **bremelanotide**, a first-in-class melanocortin receptor agonist, with **renin-angiotensin-aldosterone system (RAAS) inhibition therapy** is under clinical investigation for the treatment of diabetic nephropathy (diabetic kidney disease). Bremelanotide activates melanocortin receptors (notably MC1R, MC3R, MC4R, MC5R), resulting in anti-inflammatory and pro-resolving effects on tissue and kidney homeostasis. RAAS inhibitors (including ACE inhibitors or ARBs) are standard-of-care for diabetic nephropathy, reducing progression of kidney damage by modulating blood pressure and glomerular hemodynamics. This combination aims to synergistically reduce proteinuria and preserve kidney function by addressing both hemodynamic and inflammatory factors of disease, as demonstrated in the Phase IIb BREAKOUT study[1][2][4][6].